Vator Securities advises ExpreS2ion on 60 MSEK Rights Issue
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%.
The case
ExpreS2ion’s breast cancer vaccine candidate, ES2B-C001, is currently planned to proceed to a Phase 1 clinical trial in 2024
ExpreS2ion’s proprietary platform, ExpreS2™, enables and has been used to produce safe, effective, and long-lasting vaccines – while being versatile enough to address several of the world’s biggest unmet medical needs in cancer and infectious diseases
The platform is clinically validated through a previous partnership with Bavarian Nordic for ABNCoV2 (COVID-19 vaccine), highlighting the significance of the Phase II 12-month Ab durability data, which demonstrated long-term protection and met its primary Phase 3 endpoint (non-inferiority) as a booster vaccine to Comirnaty, Pfizer/BioNTech's mRNA vaccine
ES2B-C001, breast cancer vaccine, has recently completed GLP preclinical safety toxicology studies and is currently undergoing CTA readiness activities. The vaccine could offer significant benefits compared to current treatments
Breast cancer is the most common cancer in the world. In 2020, 2.3 million women were diagnosed with breast cancer, resulting in 685,000 deaths globally